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Abstract
Background: Globally, arthropod-borne virus infections are increasingly common causes of severe febrile disease
that can progress to long-term physical or cognitive impairment or result in early death. Because of the large
populations at risk, it has been suggested that these outcomes represent a substantial health deficit not captured
by current global disease burden assessments.
Methods: We reviewed newly available data on disease incidence and outcomes to critically evaluate the disease
burden (as measured by disability-adjusted life years, or DALYs) caused by yellow fever virus (YFV), Japanese
encephalitis virus (JEV), chikungunya virus (CHIKV), and Rift Valley fever virus (RVFV). We searched available literature
and official reports on these viruses combined with the terms “outbreak(s),”“ complication(s),”“ disability,”“ quality of
life,”“ DALY,” and “QALY,” focusing on reports since 2000. We screened 210 published studies, with 38 selected for
inclusion. Data on average incidence, duration, age at onset, mortality, and severity of acute and chronic outcomes
were used to create DALY estimates for 2005, using the approach of the current Global Burden of Disease
framework.
Results: Given the limitations of available data, nondiscounted, unweighted DALYs attributable to YFV, JEV, CHIKV,
and RVFV were estimated to fall between 300,000 and 5,000,000 for 2005. YFV was the most prevalent infection of
the four viruses evaluated, although a higher proportion of the world’s population lives in countries at risk for
CHIKV and JEV. Early mortality and long-term, related chronic conditions provided the largest DALY components
for each disease. The better known, short-term viral febrile syndromes caused by these viruses contributed
relatively lower proportions of the overall DALY scores.
Conclusions: Limitations in health systems in endemic areas undoubtedly lead to underestimation of arbovirus
incidence and related complications. However, improving diagnostics and better understanding of the late
secondary results of infection now give a first approximation of the current disease burden from these widespread
serious infections. Arbovirus control and prevention remains a high priority, both because of the current disease
burden and the significant threat of the re-emergence of these viruses among much larger groups of susceptible
populations.
Background
Arthropod-borne viral infections, or arboviral infections,
are common causes of disabling fever syndromes world-
wide, but their cumulative impact on global disease bur-
den has not been fully assessed. In their acute stages,
arboviral infections cause a broad spectrum of disease,
ranging from asymptomatic infection to severe undiffer-
entiated fever. They can also progress to much more
complex secondary conditions, or sequelae, such as
encephalitis or hemorrhagic diathesis, which result in
long-term physical and cognitive impairment or in early
death [1,2].
More than 100 arboviruses are known to cause dis-
ease in humans. A significant subset, including mem-
bers of the Flaviviridae, Bunyaviridae,a n dTogaviridae
families, are transmitted widely in different areas of
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viruses are best known for their propensity to cause
encephalitis and/or viral hemorrhagic fever (VHF) syn-
dromes [1-4]. Arboviruses are also considered to be
emerging pathogens based on their geographic spread
and their increasing impact on susceptible human
populations [5-14]. As an example, dengue virus
(DENV) infections, once rare, are now estimated to
cause > 50 million clinical cases per year following a
resurgence in Asia and renewed spread through Cen-
tral and South America [15].
As with other tropical diseases, the disabling seque-
lae of arboviruses disproportionately affect resource-
poor communities through chronic impairment of
individual performance in activities of daily living [16].
Long-term longitudinal studies of the impact of child-
hood arbovirus infections remain few in number, parti-
cularly for post-encephalitic complications, meaning
that the lifetime burden of these infections is not well
understood [17-19]. Of note, it is not just the severe
forms of acute arbovirus-related illness but also the
nominally milder forms of arboviral infection that can
result in long-lasting impairment, as has been best
described for neurologic and ophthalmologic complica-
t i o n so fW e s tN i l ev i r u s( W N V )infection [20-26]. Fre-
quent neurological impairment, lasting weeks to years,
has now also been recognized in association with
chikungunya virus (CHIKV) and dengue infection [2].
Less well known are the medium- to long-term
(months to years duration) ocular complications that
can occur after arboviral infection. Rift Valley fever
virus (RVFV) [27-32], WNV [33-39], DENV [40-47],
and CHIKV [48-51] all cause inflammatory ophthalmo-
logic complications, including chorioretinitis, uveitis,
iridocyclitis, and optic neuritis. With WNV, when such
post-infectious, long-term sequelae occur, most
patients recover within the two years following the
onset of illness [52-54]. However, this is not the case
for Japanese encephalitis virus (JEV) infection, in
which post-encephalitic neurologic injury and disability
are most often permanent [55,56]. Newer evidence also
suggests that CHIKV infection can also cause signifi-
cant physical and mental impairment for > 30 months
after infection [57]. At present, only the disease burden
caused by dengue and JEV infections are included in
World Health Organization (WHO) Global Burden of
Disease (GBD) estimates [58]. For other arboviruses,
any significant cause-specific early mortality or any
long-term infection-related morbidity (particularly as a
lifetime effect of childhood disease) represent a sub-
stantial health deficit not currently captured by disease
burden assessments, and hence are not included in
top-level discussions of disease control priorities
[58-61].
Figure 1 Countries having transmission of the four arthropod-borne viruses included in this study: yellow fever virus, Japanese
encephalitis virus, chikungunya virus, and Rift Valley fever virus.
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the frequency of arboviral infections and the incidence
of their long-term, disabling sequelae [17-37,39-54,62],
it is now appropriate to revisit the global estimates of
the health impact of these infections. In this paper, our
aim is to review the available evidence on incidence and
disease duration and critically compare the estimated
disease burden measured in disability-adjusted life years
(DALYs) caused by four common arboviral infections:
1) Yellow fever (YFV), a disease with very high acute
mortality due to hemorrhagic complications [63];
2) Japanese encephalitis (JEV), having high rates of
both acute mortality and very long-term neurologic dis-
ability [55,56,64];
3) Chikungunya virus (CHIKV) fever, a disease with
low mortality but high rates of post-infectious rheuma-
tologic and neurologic morbidity [48,65,66];
4) Rift Valley fever (RVFV), having intermediate rates
of mortality and of long-term ocular and neurologic
morbidity [28,30,31,67,68].
Methods
Setting for the analysis
In deriving our disease burden assessments for the arbo-
viruses under study, we chose to develop DALY estimates
for the disease comparisons presented in this paper. To do
so, we incorporated the following assumptions:
￿ The population of interest is the 2005 world popu-
lation, listed by country, as quantified according to
the estimates given in the United States Census
Bureau’s International Database (http://www.census.
gov/ipc/www/idb/index.php).
￿ The global and regional disease burden of each
study disease is measurable in DALYs, developed as
previously described in WHO and World Bank pub-
lications [59] and modified by the Disease Control
Priorities Project [61].
￿ DALY scores for each condition represent the sum
of two components: a) for cases of mortality, the
years of healthy life lost (YLL) from a standard
expected years of life lost (SEYLL), plus b) for indivi-
duals having nonlethal, disease-specific disability, the
years lived with disability times a disability weight
reflecting the proportion of impairment caused by
that health condition (YLD) [69].
￿ Different from the original DALY concept [69],
which employed age-weighting, and in accord with
more recent usage [60], we report both 3% time-dis-
counted, unweighted DALYs (indicated as DALY
(3,0)) and nondiscounted, unweighted DALYs (indi-
cated as DALY (0,0)) for each condition. [See [69] for
a detailed discussion on age-weighting and discount-
ing.] Our intention is to make the current estimates
align with contemporary discussions of global
health risks and the Global Burden of Disease (http://
www.who.int/healthinfo/global_burden_disease/en/
index.html).
Data collection
DALY summary calculations rely on the best available,
evidence-based estimates of yearly incidence, mortality,
average age at death, and, for nonlethal cases, informa-
tion on the duration and impact (disability weight) of
cause-specific disability outcomes related to the dis-
ease. We searched the available published literature
and official reports on YFV, JEV, CHIKV and RVFV,
focusing on the years since 2000. In order to capture
the impact of endemic disease, we excluded studies
and reports of disease among travelers from nonen-
demic areas. Searching was initiated with the use of
the arbovirus name and the terms “outbreaks,”“ com-
plications,”“ disability,”“ quality of life,”“ DALY,” and
“QALY” in PubMed and Google Scholar, and contin-
ued with hand searching of bibliographies of the
selected publications. Each publication or report was
evaluated by two authors, and the relevant information
was extracted. Publications had to meet three inclusion
criteria: 1) discussion of complications that lead to
mortality or prolonged morbidity; 2) focus on popula-
tion-based information, including incidence and/or
prevalence; and 3) published after 2000. We screened
210 published studies, of which 38 were selected for
inclusion. Additional tables and charts from US Cen-
ters for Disease Control and Prevention and WHO
publications were included in the data collection.
DALY calculations
Nondiscounted and time-discounted DALY estimates
for each disease were calculated according to standard
methods (but with only uniform age weighting [69])
using spreadsheets developed by the authors. Because of
limitations in the available data (see Results), our sum-
mary estimates were calculated for both sexes together,
and not distributed according to age group, as ideally
presented in DALY tables [59,60]. Additionally, we pre-
sent our DALY estimates as a range of credible values
based on uncertainties or potential variability of the
input values. The range of inputs for incidence of symp-
tomatic cases, associated case fatality, median age at
death, and duration of post-infection disability were
taken from the included reports.
Disability weights (DW) for acute JEV disease and
c h r o n i cs e q u e l a ew e r et a k e nf r o mM u r r a ya n dL o p e z
[59] and Mathers et al. [58] (Table 1). For the other
study arboviruses, the range of DWs for severe acute
febrile illness were based on published estimates for
LaBeaud et al. Population Health Metrics 2011, 9:1
http://www.pophealthmetrics.com/content/9/1/1
Page 3 of 11analogous acute viral syndromes that were ranked in the
original GBD framework, i.e., dengue (DW = 0.172 -
0.211) or JEV (DW = 0.616) [59]. DWs for chronic neu-
rological and visual impairment sequelae of the studied
arbovirus infections were based on closely analogous
syndromes ranked within the GBD framework, i.e.,
those for post-encephalitic cognitive impairment (DW =
0.469-0.485) and other neurologic sequelae (DW =
0.388-0.468) listed for JEV, for lameness after poliomye-
litis (DW = 0.369), and for infection-related blindness
(DW = 0.600) or low vision (0.223-0.245) following tra-
choma [59] (see Table 1).
Note on incidence estimates for arbovirus infections
Arbovirus infections typically occur in epidemics. Due
to seasonal and weather-related changes in arthropod-
borne transmission of arboviruses and periodic fluctua-
tions in the number of susceptible humans within an
area [70,71], there may be significant variation in the
local, regional, and global number of cases from year
to year. Nevertheless, for planning purposes and for
creation of comparable DALY estimates, it is impor-
tant to estimate an annualized number of affected
cases, as presented in the Results. It is also recognized
that, for some arboviruses, only a small fraction of
infected humans will become clinically symptomatic
[72,73]. For this reason, our annualized incidence
rates, case-fatality rates, and acute-to-chronic-disease
case conversion rates are based on reported or
informed estimates of the numbers of clinical cases of
arbovirus-related symptomatic disease, and not on
serologic evidence of local arbovirus transmission to
humans (see schema in Figure 2). Although during
epidemic periods, clinical case rates may reach 10-150
per 100,000 in a national population [1,71,74,75], over
a period of one to three decades, annualized human
disease incidence rates for symptomatic cases from the
study arboviruses typically occur in the range of 0.2
per year per 100,000 general population (RVFV in East
Africa [27,76]), to 2.4 per year per 100,000 general
population (for JEV [77]).
Final DALY calculations based on 2005 estimates were
as follows:
DALY = YLL + YLDacute + YLDchronic, where
YLL = (Incident deaths) × (standard expected years of
life lost at median age of death)
YLDacute = (Incident cases with acute disease only)×
DWacute × (duration acute disease)
YLDchronic = (Incident cases progressing to chronic
disease) × DWchronic × (duration of chronic disease). For
calculation of DALY (3, 0) estimates, 3% per annum
time-discounting was applied to future SEYLL and dis-
ease duration values.
Sensitivity analysis
Because of substantial uncertainty about a number of
parameters involved in the DALY calculation for each
study arbovirus, we were unable to provide a “base case”
for subsequent sensitivity analysis. Instead, we present
what we believe is the most credible range for possible
DALY burdens for each virus and discuss the implica-
tions for health planning assessments.
Table 1 Sources for disability weight estimates of arbovirus-related long-term morbidities: Proxy values based on
Global Burden of Disease project disability weights for analogous health states
Arbovirus Sequelae details and expected prevalence Analogous morbidity DW from
GBD project listings [59]
DW input range
for YLD
estimations
Yellow fever
(YFV)
Zero to 2% of YFV survivors who require critical care for severe
hemorrhage or acute encephalopathy can expect protracted symptoms
ranging from mild cognitive impairment to severe disability [79]
Persisting mild cognitive
impairment ≈ malnutrition, DW =
0.024
Severe psychomotor deficits ≈
severe complications of JEV, DW =
0.616
0.02-0.62
Japanese
encephalitis
(JEV)
30% to 50% of survivors can expect severe neurologic disability [72,83] JEV-associated moderate cognitive
impairment up to severe disability
[59]
0.39-0.49
Chikungunya
(CHIKV)
5% to 50% of survivors will have prolonged post-infectious
rheumatologic and neurologic complications [57,85,86]
≈ Osteoarthritis, DW = 0.156
or
≈ Rheumatoid arthritis, DW = 0.233
0.16-0.23
Rift Valley
fever (RVFV)
4% to 10% of survivors develop prolonged ocular and neurologic
complications of ophthalmitis and meningoencephalitis [27,67]
Prolonged visual impairment ≈
trachoma, DW = 0.223
Severe psychomotor deficits ≈
severe complications of JEV, DW =
0.616
0.22-0.62
Abbreviations: GBD, Global Burden of Diseases; DW, disability weight; YLD, Years lived with disability.
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Global distribution of disease
Table 2 and Figure 1 summarize the global distribution
of the four study arboviruses. Included are estimates of
the populations living in affected countries, along with
estimates of annualized average cause-specific mortality
rates and incidence of chronic disease cases due to the
four arbovirus infections.
Table 3 summarizes information abstracted by our lit-
erature review regarding the estimated average number
Figure 2 Schema of disease development and assessment of population-level disease parameters for arboviral infections. Among a
general population, susceptible (nonimmune) persons who are exposed to the bite of infected/infectious arthropods will go on to develop infection,
which may become symptomatic or remain nonsymptomatic. Transmission studies, usually based on serologic testing, provide evidence of past and
present infections among the target population, but do not quantify human disease or disability. Symptomatic disease (acute and chronic) and cause-
specific fatality may be tallied either actively (by public health outbreak investigations) or passively (by health care systems statistics or case series
reports). The generalizability of the rates reported for complications (transition to chronic disease) and for arbovirus-related fatality can vary widely
depending on the sampling frame, study design, duration of longitudinal follow-up, and accuracy of diagnostics used.
Table 2 World population affected by study arboviruses
Arbovirus Number of affected
countries
Population in endemic countries (% of global
population)
Estimated deaths per
year
a
Chronic cases per
year
a
Yellow fever 44 972,155,287 (15%) 675-30,000 0 to 1,955
Japanese
encephalitis
23 3,706,910,037 (57%) 3,500 to 15,000 7,350 to 22,500
Chikungunya 41 2,548,842,950 (39%) 33 to 25,761 1,193 to 46,453
Rift Valley fever 32 778,528,381 (12%) 4 to 91 12 to 272
a Note: These are annualized averages over combined epidemic and interepidemic periods.
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disease each year, along with the median age of onset
for symptomatic disease, the range or reported case-
fatality rates (per symptomatic case), and estimates of
the risk for progression to multiyear or permanent dis-
ability following the onset of symptomatic illness due to
infection. Evidence from the available literature suggests
that YFV may be the most prevalent infection of the
four viruses evaluated, in part because of declines in
YFV control efforts over the last several decades [78,79],
and in part due to the success of JEV vaccination pro-
grams that have reduced the annual number of world-
wide JEV cases to 50,000 or fewer [72].
To summarize specific findings of the literature review
regarding the individual study viruses:
YFV is associated with high acute mortality related to
its recognized potential to progress to its toxic phase
and hemorrhagic fever in 15% to 25% of early sympto-
matic cases [79]. This advanced form of disease has 20%
to 50% mortality [78-80]. During outbreaks, the median
age of patients is between 20 and 30 years old [1,81],
and the duration of acute illness is typically 18 to 21
days overall. Symptoms of infection are high fever, chills,
headache, muscle aches, vomiting, and backache, indi-
cating an acute disability in the range of that for dengue
hemorrhagic fever or acute JEV infection (DW = 0.2 to
0.6). Because the toxic phase of infection can lead to
shock, bleeding, kidney and liver failure, and the need
for several weeks of critical care, we also postulate a
possible 10% incidence of long-term disabling complica-
tions after successful recovery from this critical form of
the disease. In other words, about 1% to 2% of all non-
lethal symptomatic YFV infections are estimated to
result in chronic disabling disease.
JEV has a high acute mortality rate (10% to 30%)
[72,82] and for survivors, it frequently causes long-lasting
morbidity due to complex neurological complications
[72,83]. The median age of patients is less than 10 years
old among unvaccinated populations, with the majority
of deaths occurring in this phase of childhood [83]. The
duration of acute, nonlethal disease (DW = 0.616) is two
to three weeks. Although some motor deficits and move-
ment disorders improve after the acute illness, 30% to
50% of JEV survivors have long-term neurologic or
psychiatric sequelae [72,83]. These include seizures,
upper and lower motor neuron weakness, cerebellar
and extrapyramidal signs, flexion deformities of the
arms, hyperextension of the legs, cognitive deficits, lan-
guage impairment, learning difficulties, and behavioral
problems. These late outcomes of JEV infection
are probably permanent and have been rated at
DW = 0.388 to 0.485 by the Global Burden of Disease
project [59,60].
CHIKV infection has lower mortality among the gen-
eral population (1 per 1,000) [75], but higher mortality
(14% to 30%) among hospitalized cases with neurologi-
cal complications [84]. Symptomatic acute infection is
associated with neurological, renal, cardiac, respiratory,
hepatic, and hematological complications, with a high
risk for long term (> 30 mos) rheumatologic complica-
tions among patients older than 30 years [57,85,86].
Those patients affected by long-term, chronic symptoms
after CHIKV infection reported significant persistent
pain and impairment of activities of daily living [57,87],
with resulting decreased quality of life as measured by
formal testing [57,85]. For this post-chikungunya syn-
drome, we and others [88] have chosen to use DW
values of 0.11 to 0.23 as analogous to values for chronic
arthritides in the Global Burden of Disease framework
[59,60].
RVFV is associated with a wide range of morbidities.
Human RVFV infection is considered to be nearly
always symptomatic [89,90], typically presenting as a
syndrome of fever with nausea and arthralgias [68],
Table 3 DALY inputs: Average annualized incidence, typical age at onset, mortality, and risk for disability for studied
pathogens
Arbovirus name (common
abbreviation)
Estimated clinical cases
a
per annum
b
Median age for
symptomatic disease
Case-fatality
rate (%)
c
Survivor’s risk for multiyear or
permanent disability
Yellow fever (YFV) 30,000 to 200,000 [78] 25 yr [80,81] 2 to 15%
[78,79,81]
0 to 2% [78]
Japanese encephalitis (JEV) 35,000 to 50,000 [72,82] 10 yr [72] 10 to 30%
[72,82]
30 to 50% [72,83]
Chikungunya (CHIKV) 33,000 to 93,000
b 40 yr [84,88] 0.1 to 28%
[75,84]
5 to 50% [85,86]
Rift Valley fever (RVFV) 350 to 2,750
b 28 yr [68,104] 1 to 3.3%
[32,74]
4 to 10% [27,31]
a Clinical cases are defined as symptomatic cases requiring medical attention. Asymptomatic or inapparent infections are not included in these figures.
b Arbovirus transmission typically occurs in epidemic waves based on cyclical weather phenomena that contribute to significant increases in local abundance of
arthropod vectors. For standardized DALY comparison, where global estimates of case rates were not available, the study assumed an annualized arboviral
clinical case rate of 1.3 to 3.7/100,000 in the general population of an at-risk country.
c Rate per clinical cases (see note a, above).
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[32,67,68], uveitis/retinitis (10% to 30%) [27,31], or
hemorrhagic diathesis (1% to 3%) that is highly fatal
[32,67,68]. Average age of symptomatic disease is
between 20 and 30 years [68,76]. Average duration of
acute RVFV infection is one to two weeks, while late
neurological and visual complications are most likely
lifelong [27,67]. Disability from these late complications
was considered to be analogous to the severe neurologi-
cal sequelae of JEV or its cognitive impairment (DW =
0.39 and 0.47, respectively), and to low vision (DW =
0.22) or blindness (DW = 0.60) from trachoma.
Table 4 indicates the range of calculated global 2005
DALY estimates for each study virus based on the infor-
mation summarized above. Because of variability in esti-
mates for the incidence of the study arboviruses and the
conditional probability of death or chronic complica-
tions after acute disease, we calculated a range of DALY
values for each pathogen based on an annualized aver-
age number of symptomatic cases each year. Our results
indicate a probable range for the aggregate, nondis-
counted, uniformly weighted DALY (0,0) burden equal
to 307,082 to 5,057,081 DALYs, and a 3% discounted,
uniformly weighted DALY (3,0) of 127,681 to 2,385,203
for these pathogens combined for the world population.
Discussion
The four arboviral infections were chosen to highlight
the broad range of their associated mortality and short-
and long-term disability. The estimates presented here
extend earlier work on the DALY impact of arboviral
infections on global health [60]. Our combined 2005
DALY (3,0) estimates of 127,681 to 2,385,203, based on
disease and mortality rates taken from published
research and official reports, are in line with previously
published estimates for dengue (529,000 DALYs (3,0))
and for JEV (604,000 DALYs (3,0)) for 2001. The varia-
tion between estimates indicates the difficulty of deriv-
ing precise point estimates for these diseases based on
currently available data [58]. Data were limited for age-
and sex-specific case rates and for the likelihood of
chronic sequelae from these four arboviral infections.
Often, data were collected only during outbreaks, and
therefore, interepidemic transmission of these infections
was not included. Despite these limitations, the findings
suggest a persistent, nonnegligible world disease burden
due to arboviral disease that requires further attention
in research and public health agendas.
Perceptions about the actual frequency of arboviral
disease are changing. As better diagnostics are intro-
duced in at-risk areas, more accurate case finding allows
for better definition of the risk of symptomatic disease
and the long-term sequelae of infection [91,92]. Inherent
in the DALY calculations, it is YLL from cause-specific
mortality and the years lived with long-term, advanced
disability that provide the largest proportion of DALY
values associated with these conditions. Careful, multi-
year longitudinal follow-up (as reported for WNV in the
US [20-22,24,25,93]) will be needed to define these rates
more accurately.
Misclassification in diagnosis has also played a role in
the underestimation of viral disease burden. Arbovirus
infections are common causes of severe disease but
mimic other infections, such as acute malaria, and are
frequently misdiagnosed as such [4,94]. Better diagnosis
and careful post-mortem studies indicate that a
Table 4 Calculated global 2005 DALY estimates for the four study viruses–yellow fever, Japanese encephalitis,
chikungunya, and Rift Valley fever, based on data from previous tables
2005 Nondiscounted DALYs (0,0)
Arbovirus 2005 YLLs 2005 YLDs 2005 DALYs (0,0)
a YLLs per death YLDs per acute case YLDs per chronic case
Yellow fever 38,475-1,710,000 303-73,704 38,827-1,774,049 57 0.012-0.024 1.43-35.3
Japanese encephalitis 252,000-1,080,000 13,660-1,002,006 265,778-1,859,170 72 0.012-0.024 1.43-44.5
Chikungunya 1,386-1,081,962 405-456,898 2,124-1,411,904 2-42 0.012-0.024 0.22-9.79
Rift Valley fever 192-4,901 158-7,236 353-11,958 42 0.006-0.06 12.6-26
Total 292,053-3,876,863 14,526-1,539,844 307,082-5,057,081 –– –
2005 Discounted DALYs (3,0)
Arbovirus 2005 YLLs 2005 YLDs 2005 DALYs (3,0)
a YLLs per death YLDs per acute case YLDs per chronic case
Yellow fever 18,225-810,000 303-37,732 18,577-842,769 27 0.012-0.024 0.55-16.9
Japanese encephalitis 101,500-435,000 4,557-412,506 107,435-755,670 29 0.012-0.024 0.6-18.3
Chikungunya 759-592,503 394-260,399 1,481-780,234 23 0.012-0.024 0.21-5.56
Rift Valley fever 96-2,450 90-4,186 188-6,530 27 0.006-0.06 7.16-14.8
Total 120,580-1,839,953 5,344-714,823 127,681-2,385,203 –– –
a NOTE: Total DALY min and max do not sum across the YLL and YLD rows above because gains in one DALY category column (e.g., YLL) are necessarily offset
by reductions in survival and reduction in possible YLDs.
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malaria” cases can be due to other infectious and nonin-
fectious causes [95]. As true malaria prevalence wanes
with successful prevention and treatment campaigns,
arboviruses are poised to become the most frequent
cause of severe febrile illness throughout the world. As
shown in Figure 1 and Table 2, many countries and a
large segment of the world’s population are at risk for
arboviral transmission. Of special note, malaria control
programs using insecticide-treated bed nets and indoor
residual spraying are not a panacea for arbovirus con-
trol. Though the night-biting Anopheles vectors of
malaria are strongly affected by household-based inter-
ventions, many arboviruses are transmitted by daytime-
feeding Aedes mosquitoes or by outdoor Culex spp.
mosquitoes. Thus, arbovirus transmission often occurs
outside the home while at work or in the market
[79,96], meaning that very different interventions are
needed for arbovirus vector control.
Arboviruses also have very important impacts outside
the sphere of human health. An aspect of public health
that cannot be assessed in the DALY system is the epi-
demic potential of most arboviral pathogens. While the
DALY estimates reflect a “steady-state” assessment of
disease burden in a given era, the highly unpredictable
demands of arbovirus epidemics compel the need for
policy planning regarding the provision of health care
surge capacity, the prevention of economic and political
disruption, and the blunting of the loss of food produc-
tion due to zoonotic disease in arbovirus prevention and
control. Although the current estimated clinical cases
(Table 3) and DALY estimates (Table 4) may seem
small when averaged per year over the world’sp o p u l a -
tion, substantial economic losses and health care disrup-
tion often result from a severe arboviral outbreak in a
given region [97]. For example, once RVFV is known to
be circulating in an animal herd, the World Organisa-
tion for Animal Health (OIE) places a three-year export
embargo on those animals. The embargo is economic-
ally devastating to that farm and region, already suffer-
ing from the health consequences of the RVFV
outbreak. The political, psychological, and economic
implications of reporting arbovirus outbreaks may also
contribute to intentional underreporting of these
diseases.
As the world becomes increasingly networked through
globalization and as vectors and viruses continue to
evolve, infections that were once contained in remote
tropical locations are likely to spread to new areas. Just
as WNV emerged in the United States in 1999, other
arboviral pathogens may escape control to infect large
susceptible populations [7,98-101]. Recent examples
include WNV [14] and chikungunya [102,103]. Because
no specific medical treatment exists for most arboviral
infections, continuing public health surveillance for vec-
tor-borne infections and continuing vector control (out-
side the standard health care delivery systems) are
crucial to prevent these diseases and the morbidity and
mortality that result from them. Likewise, vaccine devel-
opment for arboviruses remains a priority because of
their outbreak potential. Recent evidence suggests a
surge in YFV cases due to the decline in YFV control
and vaccination efforts, highlighting the precarious dom-
inance we have over these infections and the immediate
increase in disease burden resulting from lack of persis-
tent focus on surveillance and control [78,79]. Ulti-
mately, due to the externalities of arbovirus outbreaks,
the development of new arboviral vaccines for common
pathogens, such as dengue, may prove extremely cost-
effective in terms of economic costs, even if their DALY
impact is more modest.
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